Perjeta

Roche's melanoma combo "too expensive" for NHS use, says NICE

NICE arrived at a similar conclusion when it published a review of breast cancer drugs Perjeta (pertuzumab) in May and Kadcyla (trastuzumab-emtansine) at the end of last year.

Roche says Tecentriq "off to a good start"

Strong gains for Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine) reinforced a 5% increase for HER2 stalwart Herceptin (trastuzumab) to 3.4bn francs.

NICE rejects Roche's breast cancer drug Perjeta

Perjeta is used alongside Herceptin or docetaxel to reduce the volume of breast tumours before surgery, making it easier to carry out the operation. ... The preliminary recommendations are open for comment until June 13, and any patient already on

Cancer drugs help Roche beat expectations in first quarter

Co. Among Roche's newer products, breast cancer drug Perjeta (pertuzumab) grew 33% to CHF439m thanks to increased use in combination with Herceptin in HER2-positive breast cancer, while arthritis medication

Roche shares slip as profits miss expectations

and Perjeta (pertuzumab) - which collectively grew 19% to CHF 8.76bn.

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]